This trial is testing a new drug, PPM, for bladder cancer. PPM is tiny particles that contain the chemotherapy drug paclitaxel. PLZ4 is a molecule that can possibly guide PPM to specifically target and deliver paclitaxel into and kill bladder cancer cells. In this trial, PPM will be instilled into the bladder cavity to treat bladder cancer that does not invade into the muscle layer of the bladder and that has failed the treatment of another drug BCG. Up to 29 patients will be enrolled into the trial. The main goal of this trial is to determine the dose of PPM for future clinical trials, assess
1 Primary · 1 Secondary · Reporting Duration: within 6 hours after administration
Experimental Treatment
29 Total Participants · 1 Treatment Group
Primary Treatment: PLZ4-coated paclitaxel-loaded micelles (PPM) · No Placebo Group · Phase 1
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: